This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 211 studies, archived under the term: "Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime"

Click here to filter this large number of results.

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial

Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]

Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment

An aim of the study was to investigate the efficacy and safety of noojerone (memantine) in patients with cognitive impairment comorbid to brain ischemia, stages II-III. The main group (30 patients, aged 64-86 years) was treated with noojerone in addition to standard therapy according to dosage scheme during 6 months. The control group (15 patients, […]

Rivastigmine patch for treatment of Alzheimer’s disease in clinical practice in Thailand

Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer’s disease (AD) and dementia associated with Parkinson’s disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand.; Methods: A multicentre, […]

The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer’s disease treated in routine clinical practice in Spain

Aims: Our aim was to perform a secondary analysis of a 12-month-long, non-blind, multi-centre prospective cost-of-illness study. The analysis assessed the effect of donepezil on cognitive functioning and the performance of patients with possible or probable Alzheimer’s disease, compared to that of other drugs for dementia.; Patients and Methods: A sample of 700 patients took […]

A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease

Rationale: There is increasing evidence to suggest the possible efficacy of Crocus sativus (saffron) in the management of Alzheimer’s disease (AD).; Objective: The purpose of the present investigation was to assess the efficacy of C. sativus in the treatment of patients with mild-to-moderate AD.; Methods: Fifty-four Persian-speaking adults 55 years of age or older who […]

Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients

The purpose of this study was to explore factors that influence the clinical safety and tolerability associated with galantamine administration in Thai Alzheimer’s disease patients with or without cerebrovascular disease and vascular dementia. This was an analysis of previous study. Tolerability and safety profile were analyzed according to sex, age, body weight, Thai mental state […]

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer’s disease

Background: Two sizes of rivastigmine patch (5 cm(2) and 10 cm(2)) are currently approved in the US and Europe, while a 20 cm(2) rivastigmine patch has also been tested. A 15 cm(2) rivastigmine patch may provide an optimal balance between efficacy and safety. Earlier studies have demonstrated the efficacy of rivastigmine in severe Alzheimer’s disease […]

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer’s disease – a multicentre RCT

Background: Alzheimer’s disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia […]

Akatinol memantine in patients with vascular cognitive disorders

Treatment of cognitive disorders developed in cerebrovascular pathology is an actual medical problem. Of great importance is the timed diagnosis of these changes in the earlier phases of the development of cognitive deficit as well as adequate therapy that can delay and prevent the development of such complication as dementia. Pathogenetic mechanisms of cognitive disorders […]

Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer’s disease in Spain (MEMORY study)

Aim: Memantine is the most recently introduced therapy for the treatment of moderately severe to severe Alzheimer’s disease. The aim of this study was to evaluate safety and effectiveness of memantine under normal clinical practice in patients with moderately severe to severe Alzheimer’s disease. Additionally, we assessed the usual prescription guidelines for memantine.; Patients and […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: